ARTICLE | Company News
On strength of first LGMD data, Sarepta exercises option to buy Myonexus
February 27, 2019 3:47 PM UTC
Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed efficacy data from a Phase I/II trial of one of the candidates, MYO-101, in a cohort of patients with LGMD type 2E; the results exceeded expectations.
On Wednesday, Sarepta shares gained $11.64 to $151.68, adding more than $800 million to the company's market cap...